Reproductive Health

FDA Approval Introduces a First-in-Class Neurokinin Receptor Agonist Shown to Reduce Vasomotor Symptom Frequency and Improve Sleep Quality in Postmenopausal Women

How can a natural biological evolution with so many consequences get relatively little attention from research and practice?

Research highlights significant barriers to contraceptive use and reproductive health management for women with chronic kidney disease (CKD), urging improved nephrology care.

Research highlights the link between earlier menopause, cardiac function, and brain health, emphasizing the need for sex-specific dementia risk strategies.

Research highlights the impact of provider type on menopause treatment, revealing a need for standardized education to improve care quality for women.

The authors wrote that their findings show a necessary update following early data from the Women’s Health Initiative.

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

New clinical trial results suggest G-CSF as a promising alternative for managing hot flashes in menopausal women, without the risks of traditional therapies.

Research highlights the impact of sleep disturbances and vasomotor symptoms (VMS) on HRQoL in women transitioning to menopausal period, emphasizing the need for effective management.

When treating vasomotor symptoms (VMS), 15- and 20-mg doses of estetrol (E4) did not significantly hinder postmenopausal women’s blood pressure, including those with cardiovascular risks.

New research reveals how menopausal hormone therapy impacts cognitive health in postmenopausal women, highlighting the importance of administration routes and estrogen types.

Elinzanetant was effective in women with low vasomotor symptom (VMS) burden and those with endocrine therapy-caused VMS.

Compared with late postmenopausal women, menopausal hormone therapy (MHT) may influence certain Alzheimer disease-related biomarkers in early postmenopausal women.

Flu vaccination during pregnancy safeguards maternal and infant health, reducing severe illness risks and providing essential immunity to newborns.

This is the second generic version of mifepristone to be approved by the FDA.

Investigators emphasize that early cardiovascular risk assessments and preventive strategies are necessary for women with polycystic ovarian syndrome (PCOS).

Weight loss before IVF enhances pregnancy chances for women with obesity, potentially improving reproductive outcomes and fertility success rates.

GLP-1 receptor agonists show promise in alleviating PCOS symptoms, including weight loss and menstrual regulation, despite needing further research.

Pharmacy-based clinical services demonstrate both public health impact and financial sustainability.

A maternal inflammatory diet during pregnancy raises the risk of offspring developing type 1 diabetes, highlighting the impact of nutrition on early health.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

The change is poised to impact countless individuals who may have sought a COVID-19 vaccine this upcoming respiratory season.